Vasodilator and inotropic agents in treatment of chronic cardiac failure

Clinical experience and response in exercise performance

Karl Weber, Virginia Andrews, Gary T. Kinasewitz, Joseph S. Janicki, Alfred P. Fishman

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The sensations of breathlessness and fatigue limit the capacity of patients with chronic congestive cardiac failure (CHF) to participate in physical activities. As a result, patients with CHF gauge quality of life in terms of symptom-free activities they can undertake. Physicians attempt to alleviate these limiting symptoms and increase the exercise capacity of patients with CHF by therapeutic interventions. In recent years a variety of systemic vasodilators and inotropic agents have been introduced to aid digitalis and diuretics in improving cardiac performance in patients with CHF. Although the pumping function of the heart is enhanced at rest, it remains to be determined whether exercise tolerance is also improved. In this paper we review our clinical experience with a number of systemic vasodilators and positive inotropic agents, focusing particular attention on their influence on exercise performance in patients with CHF. This experience includes (1) 28-week double-blind study of hydraiazine vs placebo in 19 patients with CHF, (2) 52-week double-blind crossover study of trimazosin (alpha1 blockade) vs placebo in 27 patients with CHF of varying severity, and (3) open study of amrinone (positive inotropic agent) in 12 patients with CHF.

Original languageEnglish (US)
Pages (from-to)569-577
Number of pages9
JournalAmerican Heart Journal
Volume102
Issue number3 PART 2
DOIs
StatePublished - Jan 1 1981
Externally publishedYes

Fingerprint

Vasodilator Agents
Heart Failure
Exercise
Therapeutics
Double-Blind Method
Amrinone
Placebos
Exercise Tolerance
Digitalis
Diuretics
Dyspnea
Cross-Over Studies
Fatigue
Quality of Life
Physicians

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Vasodilator and inotropic agents in treatment of chronic cardiac failure : Clinical experience and response in exercise performance. / Weber, Karl; Andrews, Virginia; Kinasewitz, Gary T.; Janicki, Joseph S.; Fishman, Alfred P.

In: American Heart Journal, Vol. 102, No. 3 PART 2, 01.01.1981, p. 569-577.

Research output: Contribution to journalArticle

Weber, Karl ; Andrews, Virginia ; Kinasewitz, Gary T. ; Janicki, Joseph S. ; Fishman, Alfred P. / Vasodilator and inotropic agents in treatment of chronic cardiac failure : Clinical experience and response in exercise performance. In: American Heart Journal. 1981 ; Vol. 102, No. 3 PART 2. pp. 569-577.
@article{682e8e317f2b4e2dba73788aec2fc62f,
title = "Vasodilator and inotropic agents in treatment of chronic cardiac failure: Clinical experience and response in exercise performance",
abstract = "The sensations of breathlessness and fatigue limit the capacity of patients with chronic congestive cardiac failure (CHF) to participate in physical activities. As a result, patients with CHF gauge quality of life in terms of symptom-free activities they can undertake. Physicians attempt to alleviate these limiting symptoms and increase the exercise capacity of patients with CHF by therapeutic interventions. In recent years a variety of systemic vasodilators and inotropic agents have been introduced to aid digitalis and diuretics in improving cardiac performance in patients with CHF. Although the pumping function of the heart is enhanced at rest, it remains to be determined whether exercise tolerance is also improved. In this paper we review our clinical experience with a number of systemic vasodilators and positive inotropic agents, focusing particular attention on their influence on exercise performance in patients with CHF. This experience includes (1) 28-week double-blind study of hydraiazine vs placebo in 19 patients with CHF, (2) 52-week double-blind crossover study of trimazosin (alpha1 blockade) vs placebo in 27 patients with CHF of varying severity, and (3) open study of amrinone (positive inotropic agent) in 12 patients with CHF.",
author = "Karl Weber and Virginia Andrews and Kinasewitz, {Gary T.} and Janicki, {Joseph S.} and Fishman, {Alfred P.}",
year = "1981",
month = "1",
day = "1",
doi = "10.1016/0002-8703(81)90746-8",
language = "English (US)",
volume = "102",
pages = "569--577",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3 PART 2",

}

TY - JOUR

T1 - Vasodilator and inotropic agents in treatment of chronic cardiac failure

T2 - Clinical experience and response in exercise performance

AU - Weber, Karl

AU - Andrews, Virginia

AU - Kinasewitz, Gary T.

AU - Janicki, Joseph S.

AU - Fishman, Alfred P.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - The sensations of breathlessness and fatigue limit the capacity of patients with chronic congestive cardiac failure (CHF) to participate in physical activities. As a result, patients with CHF gauge quality of life in terms of symptom-free activities they can undertake. Physicians attempt to alleviate these limiting symptoms and increase the exercise capacity of patients with CHF by therapeutic interventions. In recent years a variety of systemic vasodilators and inotropic agents have been introduced to aid digitalis and diuretics in improving cardiac performance in patients with CHF. Although the pumping function of the heart is enhanced at rest, it remains to be determined whether exercise tolerance is also improved. In this paper we review our clinical experience with a number of systemic vasodilators and positive inotropic agents, focusing particular attention on their influence on exercise performance in patients with CHF. This experience includes (1) 28-week double-blind study of hydraiazine vs placebo in 19 patients with CHF, (2) 52-week double-blind crossover study of trimazosin (alpha1 blockade) vs placebo in 27 patients with CHF of varying severity, and (3) open study of amrinone (positive inotropic agent) in 12 patients with CHF.

AB - The sensations of breathlessness and fatigue limit the capacity of patients with chronic congestive cardiac failure (CHF) to participate in physical activities. As a result, patients with CHF gauge quality of life in terms of symptom-free activities they can undertake. Physicians attempt to alleviate these limiting symptoms and increase the exercise capacity of patients with CHF by therapeutic interventions. In recent years a variety of systemic vasodilators and inotropic agents have been introduced to aid digitalis and diuretics in improving cardiac performance in patients with CHF. Although the pumping function of the heart is enhanced at rest, it remains to be determined whether exercise tolerance is also improved. In this paper we review our clinical experience with a number of systemic vasodilators and positive inotropic agents, focusing particular attention on their influence on exercise performance in patients with CHF. This experience includes (1) 28-week double-blind study of hydraiazine vs placebo in 19 patients with CHF, (2) 52-week double-blind crossover study of trimazosin (alpha1 blockade) vs placebo in 27 patients with CHF of varying severity, and (3) open study of amrinone (positive inotropic agent) in 12 patients with CHF.

UR - http://www.scopus.com/inward/record.url?scp=0019506589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019506589&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(81)90746-8

DO - 10.1016/0002-8703(81)90746-8

M3 - Article

VL - 102

SP - 569

EP - 577

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3 PART 2

ER -